155 related articles for article (PubMed ID: 20231859)
1. ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies.
Xu B; Tong N; Li JM; Zhang ZD; Wu HF
Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):270-7. PubMed ID: 20231859
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer.
Xu J; Zheng SL; Carpten JD; Nupponen NN; Robbins CM; Mestre J; Moses TY; Faith DA; Kelly BD; Isaacs SD; Wiley KE; Ewing CM; Bujnovszky P; Chang B; Bailey-Wilson J; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB
Am J Hum Genet; 2001 Apr; 68(4):901-11. PubMed ID: 11254448
[TBL] [Abstract][Full Text] [Related]
3. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer.
Severi G; Giles GG; Southey MC; Tesoriero A; Tilley W; Neufing P; Morris H; English DR; McCredie MR; Boyle P; Hopper JL
J Natl Cancer Inst; 2003 Jun; 95(11):818-24. PubMed ID: 12783937
[TBL] [Abstract][Full Text] [Related]
4. Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study.
Stanford JL; Sabacan LP; Noonan EA; Iwasaki L; Shu J; Feng Z; Ostrander EA
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):876-81. PubMed ID: 14504198
[TBL] [Abstract][Full Text] [Related]
5. HPC2/ELAC2 gene variants associated with incident prostate cancer.
Adler D; Kanji N; Trpkov K; Fick G; Hughes RM
J Hum Genet; 2003; 48(12):634-638. PubMed ID: 14625808
[TBL] [Abstract][Full Text] [Related]
6. A Study of Ser217Leu and Ala541Thr Polymorphism in the Men Afflicted with Prostate Cancer and in the Men being Suspicious of Prostate Cancer.
Zahiri Z; Zahiri F
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1551-1557. PubMed ID: 32592348
[TBL] [Abstract][Full Text] [Related]
7. Role of HPC2/ELAC2 in hereditary prostate cancer.
Wang L; McDonnell SK; Elkins DA; Slager SL; Christensen E; Marks AF; Cunningham JM; Peterson BJ; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
Cancer Res; 2001 Sep; 61(17):6494-9. PubMed ID: 11522646
[TBL] [Abstract][Full Text] [Related]
8. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men.
Takahashi H; Lu W; Watanabe M; Katoh T; Furusato M; Tsukino H; Nakao H; Sudo A; Suzuki H; Akakura K; Ikemoto I; Asano K; Ito T; Wakui S; Muto T; Hano H
Int J Cancer; 2003 Nov; 107(2):224-8. PubMed ID: 12949798
[TBL] [Abstract][Full Text] [Related]
9. Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study.
Chen YC; Giovannucci E; Kraft P; J Hunter D
Carcinogenesis; 2008 May; 29(5):999-1004. PubMed ID: 18375959
[TBL] [Abstract][Full Text] [Related]
10. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer.
Yokomizo A; Koga H; Kinukawa N; Tsukamoto T; Hirao Y; Akaza H; Mori M; Naito S
Prostate; 2004 Nov; 61(3):248-52. PubMed ID: 15368467
[TBL] [Abstract][Full Text] [Related]
11. Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population.
Suzuki K; Ohtake N; Nakata S; Takei T; Matsui H; Ono Y; Nakazato H; Hasumi M; Koike H; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
Anticancer Res; 2002; 22(6B):3507-11. PubMed ID: 12552947
[TBL] [Abstract][Full Text] [Related]
12. Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series.
Fujiwara H; Emi M; Nagai H; Nishimura T; Konishi N; Kubota Y; Ichikawa T; Takahashi S; Shuin T; Habuchi T; Ogawa O; Inoue K; Skolnick MH; Swensen J; Camp NJ; Tavtigian SV
J Hum Genet; 2002; 47(12):641-8. PubMed ID: 12522685
[TBL] [Abstract][Full Text] [Related]
13. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer.
Rökman A; Ikonen T; Mononen N; Autio V; Matikainen MP; Koivisto PA; Tammela TL; Kallioniemi OP; Schleutker J
Cancer Res; 2001 Aug; 61(16):6038-41. PubMed ID: 11507049
[TBL] [Abstract][Full Text] [Related]
14. Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso.
Traoré ADD; Ky BD; Traoré L; Zohoncon TM; Zouré AA; Yonli AT; Sombié HK; Sorgho PA; Elvira Bazié BVJT; Tovo SFA; Kadanga E; Bakyono BS; Traore K; Ouédraogo TC; Djigma FW; Simpore J
Prostate Cancer; 2022; 2022():3610089. PubMed ID: 36643816
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of HPC2/ELAC2 and SRD5A2 (5α-Reductase Type II) Genes in Prostate Cancer.
Izmirli M; Arikan B; Bayazit Y; Alptekin D
Balkan J Med Genet; 2011 Jun; 14(1):31-6. PubMed ID: 24052700
[TBL] [Abstract][Full Text] [Related]
16. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases.
Robbins CM; Hernandez W; Ahaghotu C; Bennett J; Hoke G; Mason T; Pettaway CA; Vijayakumar S; Weinrich S; Furbert-Harris P; Dunston G; Powell IJ; Carpten JD; Kittles RA
Prostate; 2008 Dec; 68(16):1790-7. PubMed ID: 18767027
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer.
Camp NJ; Tavtigian SV
Am J Hum Genet; 2002 Dec; 71(6):1475-8. PubMed ID: 12515253
[No Abstract] [Full Text] [Related]
18. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer.
Wu YQ; Chen H; Rubin MA; Wojno KJ; Cooney KA
Cancer Res; 2001 Dec; 61(24):8651-3. PubMed ID: 11751379
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls.
Suarez BK; Gerhard DS; Lin J; Haberer B; Nguyen L; Kesterson NK; Catalona WJ
Cancer Res; 2001 Jul; 61(13):4982-4. PubMed ID: 11431329
[TBL] [Abstract][Full Text] [Related]
20. Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men.
Izmirli M; Arikan B; Bayazit Y; Alptekin D
Asian Pac J Cancer Prev; 2011; 12(3):731-3. PubMed ID: 21627373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]